Full-length Five-pass Transmembrane Proteins
Gastric cancer is an invasive disease, and it is one of the diseases with the highest mortality in the world. Cancer stem cells (CSCs) play an important role in chemotherapy resistance, tumor initiation, invasion and metastasis. CD133 has been reported as a marker of CSCs in various tumors.
The mechanism of CD133 regulating gastric cancer progression
CD133 can be used as a prognostic marker as well as a biomarker of tumor spread under circulating conditions, and targeting CD133+ cells may be a potential new strategy for tumor regression. Further study of the different pathways by which cells control CD133 levels is necessary for the diagnosis and management of gastric cancer progression.
Relying on the "FLAG" technology platforms, ACROBiosystems has developed the full-length CD133 proteins expressed by HEK293 to meet your research and development needs for targeting CD133.
★ Full-length CD133 protein with native and complete conformation
★ High biological activity verified by binding to antibodies
★ 100-300 nm in size and high identity verified by DLS, can be used as an optimal target for dendritic cells and phage display
★ Suitable for immunization/ELISA/SPR/BLI/cell-based assay, etc.